Mostrando 8 resultados de: 8
Filtros aplicados
Subtipo de publicación
Article(8)
Publisher
Cancer Biology and Therapy(2)
Frontiers in Oncology(2)
BMC cancer(1)
Clinical Cancer Research(1)
Journal of Immunotherapy(1)
Área temáticas
Enfermedades(8)
Cirugía y especialidades médicas afines(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Origen
scopus(8)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusDifferential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
ArticleAbstract: Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cPalabras claves:immunotherapy, long-term survival, non–small cell lung cancer, survival mixture modelsAutores:Alfonso S., Carmen Elena Viada, Lage Davila A., Luaces P.L.o., Muchene L., Neninger Vinageras E., Rodríguez P.C., Sánchez L., Shkedy Z., Tania CrombetFuentes:scopusNimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience
ArticleAbstract: Nimotuzumab, a humanized antibody targeting epidermal growth factor receptor, has potent anti-prolifPalabras claves:Anaplastic astrocytoma, glioblastoma multiforme, High grade glioma, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Alert J., Chon I., Jorrín E., Luaces P.L.o., Marinello J.J.u., Miranda N., Solomón M.T.e., Tania CrombetFuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusImmunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy
ArticleAbstract: This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 gaPalabras claves:adjuvant therapy, Breast Cancer, cytotoxic antibodies, Ganglioside, NeuGcGM3, VaccineAutores:Curbelo I., Estevez A., Fernandez L.E., Gonzalez Z., Luaces P.L.o., Mazorra Z., Mulens V., Pérez K., Rubio M.C., Tania Crombet, Valdes-Zayas A., Vega A.M.Fuentes:scopusRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
ArticleAbstract: BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth FacPalabras claves:Autores:Alert J., Bach F., Ballesteros J., Catala M., de-Castro N., Domíngez R., Figueredo J., Griego M.G.o., Luaces P.L.o., Marinello J.J.u., Martell J.A.n., Quintanal N., Salva S., Selva J.C.é., Solomón M.T.e., Tania Crombet, Toledo C., Vaquer J.Fuentes:scopusThymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
ArticleAbstract: Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy rPalabras claves:Biomodulina T, CIMAvax-EGF, naïve T cells, Non-small-cell lung cancer, PD-1, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Díaz M., González A., Hernández J.d.l.C., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Molina M.d.l.A., Peña Y., Pereira K., Portela S., Ramos R., Reyes M.C., Saavedra Hernández D., Suárez G.M., Tania CrombetFuentes:scopus